According to a press release, Ginkgo aims to "develop and optimize" a microbial strain for a secondary metabolite under Syngenta's pipeline. On a scientific basis, Syngenta's research team has identified the biological solution as a high-potential asset. Financially, the partnership also offers a cost-effective approach toward large-scale production of the targeted metabolite. The agricultural technology (or agritech) market is sizable, having reached a valuation of $23.5 billion in 2022. Further, Zion Mark ...

BASEL, Switzerland and BOSTON, July 16, 2024 /PRNewswire/ -- Syngenta Crop Protection, a leader in agricultural innovation, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new collaboration aimed at accelerating the launch of a new biological solution. The two companies have previously collaborated on next-generation seed technology. Through this new collaboration, Ginkgo plans to develop and optimize a microbial strain that can ...

A recovery plan is underway, but it isn't a slam dunk. To say that Ginkgo Bioworks' (DNA -10.03%) stock is in a bit of a rough patch doesn't quite capture it. With the price of its shares down by 81% in 2024 alone, many investors are likely wishing they had walked out the door months ago. But with the biotech's ambitious vision for highly automated biopharma manufacturing still unrealized, there may yet be rewards waiting for those who hold on for a bit longer. Or shareholders could just experience even mor ...

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions. For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$0.30 per share and a revenue of $175. ...

Ginkgo Bioworks' Big Team-Up Ginkgo Bioworks: Bad News and Worse News Consequently, if the company continues to run afoul of the NYSE's listing rules, don't be too surprised if the exchange delists Ginkgo Bioworks. Getting kicked off the prestigious NYSE and relegated to the over-thecounter gulag would be a harsh blow for Ginkgo Bioworks and its loyal shareholders. There's definitely a science to picking beaten-down gems in the stock market. If you get it wrong, you could lose a lot of money. Ginkgo Biowork ...

Ginkgo Bioworks (NYSE:DNA) layoffs continue today with the cell programming company announcing additional job cuts. Ginkgo Bioworks notes that these layoffs are part of a restructuring plan. This will see some of the job cuts happening in 2025 as it continues to alter its business. However, the initial job cuts will begin this month. More Ginkgo Bioworks Layoffs DNA stock is down 10.6% as of Wednesday afternoon. That comes with over 52 million shares traded. This is above its daily average trading volume of ...

Venlo, the Netherlands, June 11, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of 35 new wet-lab tested digital PCR Microbial DNA Detection Assays for its digital PCR (dPCR) platform QIAcuity, significantly enhancing its offerings in the field of microbial research. The new assays are available on QIAGEN's comprehensive research platform GeneGlobe and are designed to target a wide range of pathogens responsible for tropical diseases, sexually transmit ...

Morgan Stanley recently released its bullish take on the biotech space, driven by anticipated interest rate cuts and a surge in mergers and acquisitions (M&A) activity. The analyst firm states biotech stocks typically outshine the market just before a rate cut. Moreover, increased optimism spurs an uptick in M&A activity, contributing to a more active biotech sector. Hence, discarding underperforming biotech stocks to sell is imperative, as the industry is picking up steam again. Rallybio (RLYB) Source: Shu ...

This innovative biotechnology company hopes to turn things around. Once upon a time, Ginkgo Bioworks (DNA -0.25%) was viewed by many as a rising star in the biotechnology world. However, since its initial public offering in September 2021, the stock has plunged 95%. So far in 2024, Ginkgo's shares have fallen more than 60%. Can Ginkgo Bioworks stage a major comeback? Or is the stock likely to continue floundering? Two Motley Fool contributors make the bull and bear arguments for Ginkgo. Bull case: A growing ...

Its vision is ambitious, but can it actually be made to work? In the last three months, Ginkgo Bioworks' (DNA -10.27%) shares fell by 50%. To the enterprising investor, such a decline by the Boston-based biotech specialist isn't necessarily a sign of disaster, and in fact could well be a sign of an opportunity to buy shares at a discount -- assuming those shares can be reasonably expected to rise again in the future. Is that the case with this company, or would it be better to look for opportunities elsewhe ...